Who
Melanie Gloria
Chief Operating Officer
Company insider
Files Form 4 as: Chief Operating Officer, Immunovant; Chief Operating Officer, Acelyrin.
In numbers
- Trades disclosed
- 46
- Buys
- 0
- Sells
- 8
- Bought
- $0
- Sold
- $3.0M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 4 May 2023
- Last trade
- 7 Oct 2026
- Last filed
- 9 Oct 2026
Companies traded
Activity over time
1 Nov 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Oct 2026filed 9 Oct 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Sold | $72K2,241 at $32.06 | filing |
| 20 Aug 2026filed 21 Aug 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Sold | $135K3,056 at $44.16 | filing |
| 20 Aug 2026filed 21 Aug 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Sold | $135K3,056 at $44.16 | filing |
| 8 Jul 2026filed 10 Jul 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Sold | $76K1,930 at $39.53 | filing |
| 8 Jul 2026filed 10 Jul 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Sold | $4,239106 at $39.99 | filing |
| 8 Jul 2026filed 10 Jul 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Sold | $76K1,930 at $39.53 | filing |
| 8 Jul 2026filed 10 Jul 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Sold | $4,239106 at $39.99 | filing |
| 26 Jun 2026filed 26 Jun 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Sold | $563K14,748 at $38.18 | filing |
| 26 Jun 2026filed 26 Jun 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Sold | $116K2,966 at $38.95 | filing |
| 26 Jun 2026filed 26 Jun 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Sold | $563K14,748 at $38.18 | filing |
| 26 Jun 2026filed 26 Jun 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Sold | $116K2,966 at $38.95 | filing |
| 20 May 2026filed 22 May 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Sold | $7,572249 at $30.41 | filing |
| 20 May 2026filed 22 May 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Sold | $38K1,168 at $32.15 | filing |
| 20 May 2026filed 22 May 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Sold | $56K1,698 at $32.95 | filing |
| 20 May 2026filed 22 May 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Sold | $7,572249 at $30.41 | filing |
| 20 May 2026filed 22 May 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Sold | $38K1,168 at $32.15 | filing |
| 20 May 2026filed 22 May 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Sold | $56K1,698 at $32.95 | filing |
| 8 Apr 2026filed 10 Apr 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Sold | $217K8,722 at $24.83 | filing |
| 8 Apr 2026filed 10 Apr 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Sold | $217K8,722 at $24.83 | filing |
| 7 Apr 2026filed 9 Apr 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Code A | —83,671 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.